Janus_kinase.pdf

www.MedChemE 1 JAK Janus kinase? Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes. Purity: 98% Clinical Data: Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg Purity: 98% Clinical Data: Size: 5 mg, 10 mg, 50 mg, 100 mg Purity: 99.65% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Purity: 99.84% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Purity: 98.81% Clinical Data: Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Purity: 99.74% Clinical Data: Phase 1, Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Purity: 98% Clinical Data: Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg Purity: 98% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg Purity: 98% Clinical Data: Phase 3, Phase 4 Size: 5 mg Purity: 98% Clinical Data: Phase 3 Size: 5 mg JAK Inhibitors Modulators Bioactivity: To